

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A recombinantly produced or isolated polypeptide which is a fragment of RHAMM comprising ~~consisting essentially of~~ the amino acid sequence human S3 (SEQ ID NO: 74).

Claims 2-33 (cancelled)

34. (new) The polypeptide of claim 1 which is less than 250 amino acids in length.

35. (new) The polypeptide of claim 1 which is SEQ ID NO: 74.

36. (new) A recombinantly produced or isolated polypeptide of less than 250 amino acid residues comprising the amino acid sequence human S3 (SEQ ID NO: 74).

37. (new) The polypeptide of claim 36 which is SEQ ID NO: 74.

38. (new) A recombinantly produced or isolated polypeptide which is a fusion polypeptide comprising SEQ ID NO: 74 and at least one sequence selected from the group consisting of a portion of RHAMM and a heterologous sequence.

39. (new) The polypeptide of claim 38 which is less than 250 amino acids in length.

40. (new) A pharmaceutical composition comprising at least one polypeptide according to any of claims 1 or 34-39.

41. (new) The pharmaceutical composition of claim 40 for the treatment of a condition selected from the group consisting of inflammatory neurological disorders, multiple sclerosis and diabetes mellitus.

42. (new) The pharmaceutical composition of claim 40 further comprising a pharmaceutically or physiologically acceptable material selected from the group consisting of carriers, excipients and diluents.

43. (new) The pharmaceutical composition of claim 40 which is adapted for administration by a route selected from the group consisting of systemically, orally, rectally, intravenously, subcutaneously, intramuscularly, ocularly and topically.

44. (new) The pharmaceutical composition of claim 40 which is administered at a dose range selected from the group consisting of 1 ng/kg to 80 mg/kg and 0.001 mg/kg to 50 mg/kg.

45. (new) A vaccine composition comprising at least one polypeptide according to any of claims 1 or 34-39.

46. (new) The vaccine composition of claim 45 for the treatment of a condition selected from the group consisting of inflammatory neurological disorders, multiple sclerosis and diabetes mellitus.

47. (new) The vaccine composition of claim 45 which is administered using a schedule which comprises an initial immunization followed by at least one booster.

48. (new) A method of treating a condition selected from the group consisting of inflammatory neurological disorders, multiple sclerosis and diabetes mellitus comprising administering to a subject in need thereof at least one polypeptide according to any of claims 1 or 34-39.